NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Studying Eye Movement Deficits and Cognitive Impairment in Patients with Multiple Sclerosis Using Infrared Eye Tracking and Cognitive Tests
Studying Eye Movement Deficits and Cognitive Impairment in Patients with Multiple Sclerosis Using Infrared Eye Tracking and Cognitive Tests

NCT06629155

Not Yet RecruitingN/A

Sponsor: Universitair Ziekenhuis Brussel

Conditions: Multiple Sclerosis, Internuclear Ophthalmoplegia

Interventions: Infrared oculography

The goal of this observational study is to study the relationship between cognitive problems and problems in eye movements in Multiple Sclerosis (MS). The main questions it aims to answer are: * What is the correlation between eye movement parameters (VDI AUC and VDI Pv/Am, left and right) and SDMT scores in patients with MS? * What is the number of patients with VDI AUC\>1.174 and/or VDI Pv/Am\>1.180 assessed by infrared oculography during prosaccades at 15 degrees left or right? * What is the correlation between eye movement parameters (VDI AUC and VDI Pv/Am, left and right) and cognitive test scores in patients with MS? Participants will perform specific cognitive tests and eye movements will be measured through infrared oculography. The primary hypothesis for the study is: participants who exceed the treshold (VDI AUC\>1.174 and/or VDI Pv/Am\>1.180, left or right) will perform worse on cognitive tests compared to those who don't.

Eligibility overview

Sex: ALL

Age: 18 Years to

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion criteria:

* Diagnosed with clinically definite multiple sclerosis according to the 2017 McDonald criteria
* At least 18 years old
* Combined vision with optimal correction \> 0,6 on Snellen Visual Acuity Test.
* Providing informed consent.

Exclusion criteria:

* Major medical or psychiatric pathology that potentially affects cognitive functioning.
* A score higher than 63 on the Fatigue Scale for Motor and Cognitive Functions is categorized as severe fatigue
* Start or switch in immunomodulatory treatment within three months before inclusion.
* Less than 3 months post exacerbation.
* Refusing informed consent.